- Conditions
- Hepatic Encephalopathy
- Interventions
- Rifaximin
- Drug
- Lead sponsor
- Bausch Health Americas, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 322 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 31
- States / cities
- Birmingham, Alabama • Aurora, California • Fresno, California + 28 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–12
of 12
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Irritable Bowel Syndrome With Diarrhea
- Interventions
- open-label rifaximin, double-blind placebo, double-blind rifaximin
- Drug
- Lead sponsor
- Bausch Health Americas, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,583 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 293
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Dothan, Alabama + 226 more
- Conditions
- Alzheimer's Disease
- Interventions
- Rifaximin 550 milligrams (MG)
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 55 Years to 85 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Small Bowel Bacterial Overgrowth, Gastrointestinal Diseases, Stomach Diseases, Digestive System Diseases
- Interventions
- Xifaxan, SmartPill, Lactulose hydrogen breath test (H_2BT)
- Drug · Device · Procedure
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2010
- U.S. locations
- 1
- States / cities
- Scottsdale, Arizona
- Conditions
- Human Gastrointestinal Physiology Data
- Interventions
- Glucotrol XL 5Mg Extended-Release Tablet, Glipizide ER 5 MG 24 HR Extended Release Oral Tablet, Rifaximin 200Mg Tab, 13C6-Glipizide
- Drug
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Diarrhea, Gastroenteritis, Bacterial Infection, Acute Diarrhea
- Interventions
- Rifaximin 200 mg Tablet, Oral Rehydration Therapy (ORT)
- Drug · Other
- Lead sponsor
- Bausch Health Americas, Inc.
- Industry
- Eligibility
- 6 Years to 12 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 10
- States / cities
- Lynwood, California • Hialeah, Florida • Miami, Florida + 6 more
- Conditions
- Minimal Hepatic Encephalopathy
- Interventions
- rifaximin
- Drug
- Lead sponsor
- Hunter Holmes Mcguire Veteran Affairs Medical Center
- Federal
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Richmond, Virginia
- Conditions
- Parkinson's Disease
- Interventions
- Rifaximin
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 1
- States / cities
- Scottsdale, Arizona
- Conditions
- Hepatic Encephalopathy, Cirrhosis
- Interventions
- Rifaximin, Lactulose
- Drug
- Lead sponsor
- Bausch Health Americas, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 222 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 43
- States / cities
- Phoenix, Arizona • Coronado, California • Fresno, California + 35 more
- Conditions
- Severe Hepatic Impairment
- Interventions
- Rifaximin
- Drug
- Lead sponsor
- Bausch Health Americas, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Hepatic Cirrhosis, Hepatic Encephalopathy (HE)
- Interventions
- MNK6106, Rifaximin
- Drug
- Lead sponsor
- Mallinckrodt
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 4
- States / cities
- Coronado, California • Rialto, California • St. Petersburg, Florida + 1 more
- Conditions
- Microscopic Colitis
- Interventions
- Rifaximin 550mg
- Drug
- Lead sponsor
- Eugene F Yen, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- Evanston, Illinois